Can You Get Wegovy If You're Not Obese?

Step 1: Where the licensed BMI boundary actually sits

The phrase "not obese" covers a lot of ground. Clinically, obesity is defined as a BMI of 30 or above. Wegovy's UK marketing authorisation (granted by the MHRA and reflected in the NHS semaglutide medicines page) sets two distinct eligibility bands, and the lower one is specifically designed for people below that threshold. If your BMI is between 27 and 29.9, you fall into the overweight range, and the licence covers you provided you have at least one weight-related comorbidity alongside that BMI.

The conditions that satisfy this requirement include type 2 diabetes, high blood pressure, raised cholesterol or triglycerides, obstructive sleep apnoea, and established cardiovascular disease. This is not a loophole: the clinical rationale is that at a lower BMI, the health risk is driven by the comorbidity rather than the weight alone, so treating both together carries a meaningful benefit. If you sit in this bracket, the question your prescriber is really asking is whether the health condition linked to your weight is significant enough to justify the medicine.

One more layer worth knowing: for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance recognises that health risks associated with excess weight tend to appear at lower BMIs, so the standard thresholds are usually reduced by around 2.5 kg/m². A BMI of 24.5 with a comorbidity, for example, might be assessed differently depending on your background.

Step 2: What "at least one weight-related condition" means in practice

The phrase sounds neat on paper but the detail matters. Not every condition associated with weight will satisfy the licence criterion, the prescriber needs to confirm that the condition is weight-related in your specific case, not merely coincidental. Prediabetes, for instance, is widely recognised as a weight-related metabolic condition, while a knee injury might not qualify in the same way.

In practice, a prescriber will look at your current diagnoses, any medication you are already taking for those conditions, and how the comorbidity is being managed. If you are on antihypertensives, statins or metformin, those medicines are themselves evidence that a qualifying condition exists and is clinically significant. If you are not on treatment but your GP has recorded an elevated reading, that matters too and is worth mentioning when you complete a consultation.

There are also things that can rule out treatment regardless of BMI or comorbidities. Pregnancy, breastfeeding, or planning to conceive in the near term are contraindications under the licence; semaglutide is not recommended in those circumstances. Treatment is also not licensed for anyone under 18. A personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 requires discussion with a prescriber before any decision is made. The medicines that interact with Wegovy are another important part of the clinical picture your prescriber will work through with you.

Step 3: The NHS route versus a private prescription

If your BMI is below 30, the NHS route to Wegovy is narrow. NICE's appraisal of semaglutide for weight management (TA875) recommends it only within specialist weight management services, for a maximum of two years, and primarily for people with a BMI of 35 or above, or between 30 and 34.9 in specific circumstances. People with a BMI of 27–29.9 are within the medicine's licence but currently sit outside the NICE-recommended NHS population, so NHS access at that BMI is unlikely through standard routes.

Private prescribing follows the licensed criteria rather than NICE's commissioning recommendations, which is why a regulated private pharmacy can lawfully prescribe Wegovy to someone with a BMI of 27–29.9 plus a qualifying condition, provided a prescriber judges it clinically appropriate after a proper assessment. If you're weighing up the options and what a private route typically involves in terms of cost, our Wegovy pricing guide sets out what to expect and what a legitimate price actually covers. The full Wegovy treatment page also explains the titration pathway and how dispensing works from a GPhC-registered pharmacy.

Step 4: When treatment might still not be the right fit

Meeting the licence criteria is the beginning of the process, not the end. A prescriber reviewing your case will also consider whether the expected benefit is proportionate, whether you have any contraindications that override eligibility, and whether there are lifestyle factors that need to be in place for the medicine to work well. Clinical trials for Wegovy were all conducted alongside a reduced-calorie diet and increased physical activity, the medicine was designed as an addition to those measures, not a replacement for them.

There is also the question of what happens if it does not work as expected. Not everyone responds well, and understanding why Wegovy sometimes does not produce the expected weight loss is useful context before starting. Similarly, certain behaviours on treatment can reduce its effectiveness or increase side-effect risk, and there is specific guidance on what to avoid while taking Wegovy that a prescriber will talk through with you.

If you are thinking about starting, a free consultation with a GPhC-registered prescriber is the right first step. At nume, every consultation is read by a named clinician, a real person who reviews your answers and makes a clinical judgement. If treatment is suitable, your prescription is typically issued the same day, and the pen arrives the next working day via tracked DPD delivery, in a plain, unbranded box. Check your eligibility and see whether Wegovy could be appropriate for your situation.